Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Alyglo in Pediatric Primary Humoral Immunodeficiency
NCT04565015Phase 3Active, not recruiting
- Sponsor
- GC Biopharma Corp
- Start
- Dec 2020
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in Primary Humoral Immunodeficiency, sponsored by GC Biopharma Corp. Started Dec 2020; status: active, not recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Primary Humoral Immunodeficiency
Beyond the preview
Go deeper on NCT04565015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04565015.